tranexamic acid has been researched along with Chloasma in 128 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Studies have revealed reduction of erythema by oral tranexamic acid; however, there has been no direct comparison to placebo." | 9.41 | Effect of oral tranexamic acid on erythema index in patients with melasma. ( Nguyen, J; Paul, E; Rajgopal Bala, H; Rodrigues, M; Ross, A; Wong, CC, 2021) |
| "Oral tranexamic acid has been used in different types of hyperpigmentation disorder, including postinflammatory hyperpigmentation treatment and prevention, lichen planus pigmentosus, ashy dermatosis, and Riehl melanosis in a dose range from 250 mg per day to 1500 mg per day for a period range from 2 weeks to 6 months with variable efficacy and a good safety profile." | 9.41 | Oral tranexamic acid in the treatment of hyperpigmentation disorder beyond melasma: A review. ( Mahjoub, TT; Milibary, HH, 2023) |
| "To observe and analyze the efficacy of tranexamic acid combined with reduced glutathione in chloasma treatment." | 9.27 | Clinical observation on tranexamic acid combined with reduced glutathione for the treatment of chloasma. ( Feng, C; Yan, M, 2018) |
| "In this pilot study, we evaluated the efficacy and safety of a novel combination therapy with oral administration of tranexamic acid (TA) and Glycyrrhizin compound for recalcitrant Riehl's melanosis." | 7.91 | A pilot study of oral tranexamic acid and Glycyrrhizin compound in the treatment of recalcitrant Riehl's melanosis. ( Chen, L; Flora Xiang, L; Xing, X; Xu, Z; Zhang, C, 2019) |
| "In this prospective pilot study, we evaluated the efficacy and safety for a novel combination therapy based on low-fluence Q-switched 1064 nm Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's melanosis." | 7.85 | A pilot study for triple combination therapy with a low-fluence 1064 nm Q-switched Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's Melanosis. ( Choi, SC; Jung, JY; Kwon, HH; Kwon, IH; Ohn, J; Park, GH; Park, HY; Suh, DH, 2017) |
| "Melasma and vitiligo are both common pigmentary disorders, and the treatment is challenging." | 5.62 | Feasibility of oral tranexamic acid for vitiligo patients with melasma. ( Chiang, PH; Chiu, YC; Chung, WH; Ku, CL; Lin, YJ; Ng, CY, 2021) |
| "Oral tranexamic acid has been used in different types of hyperpigmentation disorder, including postinflammatory hyperpigmentation treatment and prevention, lichen planus pigmentosus, ashy dermatosis, and Riehl melanosis in a dose range from 250 mg per day to 1500 mg per day for a period range from 2 weeks to 6 months with variable efficacy and a good safety profile." | 5.41 | Oral tranexamic acid in the treatment of hyperpigmentation disorder beyond melasma: A review. ( Mahjoub, TT; Milibary, HH, 2023) |
| " Studies have revealed reduction of erythema by oral tranexamic acid; however, there has been no direct comparison to placebo." | 5.41 | Effect of oral tranexamic acid on erythema index in patients with melasma. ( Nguyen, J; Paul, E; Rajgopal Bala, H; Rodrigues, M; Ross, A; Wong, CC, 2021) |
| "To observe and analyze the efficacy of tranexamic acid combined with reduced glutathione in chloasma treatment." | 5.27 | Clinical observation on tranexamic acid combined with reduced glutathione for the treatment of chloasma. ( Feng, C; Yan, M, 2018) |
| "Tranexamic acid (TA) is an antifibrinolytic agent, increasingly recognized as being of utility for a wide variety of skin diseases." | 5.05 | The emerging importance of tranexamic acid in dermatology. ( Al-Niaimi, F; Ali, FR; Forbat, E, 2020) |
| " Tranexamic acid was used as a model drug to evaluate the suitability of formulation to prevent symmetric hyperpigmentation." | 4.12 | Design and development of tranexamic acid loaded film-forming gel to alleviate melasma. ( Chevala, NT; Dsouza, JA; Kumar, L; Saini, H, 2022) |
| "In this pilot study, we evaluated the efficacy and safety of a novel combination therapy with oral administration of tranexamic acid (TA) and Glycyrrhizin compound for recalcitrant Riehl's melanosis." | 3.91 | A pilot study of oral tranexamic acid and Glycyrrhizin compound in the treatment of recalcitrant Riehl's melanosis. ( Chen, L; Flora Xiang, L; Xing, X; Xu, Z; Zhang, C, 2019) |
| "In this prospective pilot study, we evaluated the efficacy and safety for a novel combination therapy based on low-fluence Q-switched 1064 nm Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's melanosis." | 3.85 | A pilot study for triple combination therapy with a low-fluence 1064 nm Q-switched Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's Melanosis. ( Choi, SC; Jung, JY; Kwon, HH; Kwon, IH; Ohn, J; Park, GH; Park, HY; Suh, DH, 2017) |
| " However, no clear consensus on the dosing and duration of maintenance doses of TXA therapy in melasma exists." | 3.30 | A randomized, open-label study to compare two different dosing regimens of oral tranexamic acid in treatment of moderate to severe facial melasma. ( Bhattacharjee, R; Bishnoi, A; Hanumanthu, V; Kumar, A; Kumaran, MS; Parsad, D; Thakur, V; Vinay, K, 2023) |
| "Melasma is a hyperpigmentary disorder causing cosmetic disfigurement." | 3.30 | Tranexamic acid microinjections versus tranexamic acid mesoneedling in the treatment of facial melasma: A randomized assessor-blind split-face controlled trial. ( Alizadeh, M; Fatemi Naeini, F; Poostiyan, N; Shahmoradi, Z, 2023) |
| "Treatment of melasma is challenging." | 3.11 | A prospective randomized controlled trial of Q-switched Nd:YAG laser with topical 3% tranexamic acid (TA) versus microneedling with topical 3% tranexamic acid (TA) in treatment of melasma. ( Debasmita, B; Ipsita, D; Ishan, A; Raj, C, 2022) |
| "Topical tranexamic acid or vitamin C application after dermapen microneedling was an effective and safe technique in melasma treatment with minimal side effects, and vascular component improvement by tranexamic acid." | 3.11 | Efficacy and Safety of tranexamic acid versus vitamin c after microneedling in treatment of melasma: Clinical and Dermoscopic study. ( Doghaim, N; El Attar, Y; El Far, N; El Hedody, S; Hawwam, SA, 2022) |
| "Tranexamic acid can increase the permeability locally by non-invasive methods such as microneedling which is less painful than microinjection and can also increase patient satisfaction." | 3.11 | Comparison of efficacy and safety of tranexamic acid mesotherapy versus oral tranexamic acid in patients with melasma undergoing Q-switched fractional 1064-nm Nd:YAG laser: A blinded RCT and follow-up. ( Behrangi, E; Dilmaghani, S; Ghassemi, M; Goodarzi, A; Shemshadi, M, 2022) |
| "Oral tranexamic acid (TA) is a promising drug for its treatment and may enhance outcomes when used in combination." | 3.11 | Oral tranexamic acid with a triple combination cream versus oral tranexamic acid monotherapy in the treatment of severe melasma. ( Chavez-Alvarez, S; Herz-Ruelas, ME; Martinez-Rico, JC; Ocampo-Candiani, J; Sosa-Colunga, SA; Suro-Santos, Y; Vazquez Martinez, O, 2022) |
| "Oral tranexamic acid (TXA) is a relatively new treatment option for melasma." | 3.11 | A Randomized Trial of Oral Tranexamic Acid With Fluocinolone-Based Triple Cream Versus Fluocinolone Based Triple Cream Alone for the Treatment of Melasma. ( Berger, L; Perveen, S; Rao, B; Rubin, A; Sharif, S; Waqas, N; Xiong, W, 2022) |
| "Melasma is a chronic acquired condition characterized by grayish-brown macules and patches with a distinct border on the face." | 3.11 | Fractional erbium:YAG laser (2940 nm) plus topical hydroquinone compared to intradermal tranexamic acid plus topical hydroquinone for the treatment of refractory melasma: a randomized controlled trial. ( Asilian, A; Bahrami, B; Faghihi, G; Iraji, F; Mokhtari, F, 2022) |
| "Tranexamic acid is a promising drug for melasma treatment, but its topical formulation has limited efficacy." | 3.11 | Comparative study between topical tranexamic acid alone versus its combination with autologous platelet rich plasma for treatment of melasma. ( Donia, AA; Gamea, MM; Hegab, DS; Kamal, DA, 2022) |
| " Adverse events were recorded." | 3.11 | Efficacy and safety of 755-nm picosecond alexandrite laser with topical tranexamic acid versus laser monotherapy for melasma and facial rejuvenation: a multicenter, randomized, double-blinded, split-face study in Chinese patients. ( Li, L; Li, Y; Song, Y; Yao, C; Zhang, H, 2022) |
| "Tranexamic acid is a plasmin inhibitor that is used off-label for the treatment of melasma." | 3.01 | The uses of tranexamic acid in dermatology: a review. ( Kim, KM; Lim, HW, 2023) |
| " Original studies that reported pre- and post-treatment Melasma Area Severity Index (MASI)/modified Melasma Area Severity Index (mMASI) scores and/or adverse effects (AEs) were eligible for inclusion." | 3.01 | Efficacy and safety of topical agents in the treatment of melasma: What's evidence? A systematic review and meta-analysis. ( Aljabban, A; Bain, PA; Bay, CP; Chang, YF; Chung, HJ; Desai, SR; Lee, TL; Oyerinde, O, 2023) |
| "Tranexamic acid (TA) is a potential agent, but there are few studies on its effectiveness under the transdermal route (drug delivery-Dd)." | 3.01 | Randomized, double-blind, placebo-controlled split-face trial of the efficacy of tranexamic acid by drug delivery through microneedling in the treatment of melasma. ( Costa, A; Kuster Kaminski Arida, D; Larocca Skare, T; Marioto de Campos, GL; Orso Rebellato, PR; Rodrigues Lisboa Faucz, L; Vilaverde Schmitt, J, 2021) |
| "Tranexamic acid (TA) is a potential treatment option for hyperpigmentation with different delivery routes." | 3.01 | Efficacy of topical versus intradermal injection of Tranexamic Acid In Egyptian melasma Patients: A randomised clinical trial. ( Ali, AU; Badran, AY; Gomaa, AS, 2021) |
| "Riehl's melanosis is a hyperpigmentation disorder that has a significant psychological and social impact on individuals." | 3.01 | Unveiling the mystery of Riehl's melanosis: An update from pathogenesis, diagnosis to treatment. ( Ding, Y; Xiang, LF; Xu, Z; Zhang, C, 2023) |
| "Tranexamic acid (TXA) has emerged as a potential treatment for melasma." | 3.01 | The efficacy of oral vs different dilutions of intradermal tranexamic acid microinjections in melasma-A randomized clinical trial. ( El Hadidi, H; Mosaad, R; Ragab, N, 2021) |
| "Melasma is an acquired refractory pigmentary disorder, which is a skin disease that predominantly affects females." | 3.01 | Clinical observation and dermoscopy evaluation of fractional CO ( Liu, J; Qu, Y; Wang, F; Xia, X, 2021) |
| "Tranexamic acid (TXA) is a plasmin inhibitor used off-label in the treatment of melasma." | 3.01 | Tranexamic acid in melasma: A focused review on drug administration routes. ( Balazic, E; Jaller, JA; Khanna, U; Kobets, K; Konisky, H, 2023) |
| "As relapses are frequent on discontinuation, a minimum effective dose of TXA that can be used safely for long time remains unknown." | 3.01 | Therapeutic efficacy and safety of oral tranexamic acid 250 mg once a day versus 500 mg twice a day: a comparative study. ( Chauhan, PS; Chowdhary, B; Kumar, P; Mahajan, VK; Mehta, KS; Sharma, A; Sharma, V; Vashist, S, 2021) |
| "Melasma, also known as chloasma or mask of pregnancy, is a common, acquired, hyperpigmentary disorder usually affecting females." | 3.01 | Microneedling-assisted topical tranexamic acid solution versus 4% hydroquinone for treating melasma: A split-face randomized study. ( Elsaie, ML; Khalil, EA; Obaid, ZM; Zaky, MS, 2021) |
| "Melasma is a pigmentary disorder affecting mainly face ." | 2.94 | Study of oral tranexamic acid, topical tranexamic acid, and modified Kligman's regimen in treatment of melasma. ( Jawade, S; Kulkarni, S; Madke, B; Sahu, PJ; Saoji, V; Singh, AL, 2020) |
| "Melasma is a chronic recalcitrant pigmentary disorder whose treatment frustrates physician and patient alike." | 2.94 | Efficacy and safety of oral tranexamic acid as an adjuvant in Indian patients with melasma: a prospective, interventional, single-centre, triple-blind, randomized, placebo-control, parallel group study. ( Minni, K; Poojary, S, 2020) |
| "Melasma is an acquired hyperpigmented skin disorder." | 2.94 | Tranexamic Acid for Melasma Treatment: A Split-Face Study. ( Ebrahim, HM; Gharib, K; Khattab, F; Said Abdelshafy, A, 2020) |
| "Melasma is a benign and chronic hypermelanosis characterized by irregular light brown to dark brown patches of hyperpigmentation on the skin." | 2.94 | Comparing the efficacy of Myjet-assisted tranexamic acid and vitamin C in treating melasma: A split-face controlled trial. ( Li, L; Li, M; Wang, B; Yan, Y; Zhang, X; Zhao, H, 2020) |
| "8% liposomal TA and microneedling with 5% TA solution are both effective and safe on melasma." | 2.94 | The efficacy and safety of topical tranexamic acid (liposomal or lotion with microneedling) versus conventional hydroquinone in the treatment of melasma. ( Chen, L; Jin, S; Xiang, L; Xing, X; Xu, Z; Zhang, C, 2020) |
| "Tranexamic acid (TA) has been used systemically and locally for clearance of pigmentation." | 2.94 | Clinical Efficacy of Topical Tranexamic Acid With Microneedling in Melasma. ( Bhalla, M; Kaur, A; Pal Thami, G; Sandhu, J, 2020) |
| "Melasma is a common pigmentary disorder for which oral tranexamic acid has shown some efficacy in previous studies." | 2.94 | Randomised, controlled, double-blind study of combination therapy of oral tranexamic acid and topical hydroquinone in the treatment of melasma. ( Agustin, T; Legiawati, L; Pandya, AG; Prihartono, J; Shihab, N; Tovar-Garza, A, 2020) |
| "Melasma is an acquired circumscribed hyperpigmented disorder seen mainly on the malar area of face and other parts of body." | 2.94 | New local treatments for different types of melasma: Vascular type vs nonvascular type. A randomized polycentric study. ( Fioranelli, M; Jafferany, M; Lotti, T; Tirant, M; Van Thuong, N; Wollina, U, 2020) |
| "Tranexamic acid (TA) has been shown to be effective against melasma, however, the optimal dose has not been investigated." | 2.90 | Analysis of the effect of different doses of oral tranexamic acid on melasma: a multicentre prospective study. ( Kawada, A; Li, Y; Sun, QN; Takada, A; Zhu, CY, 2019) |
| "Tranexamic acid (TA) has emerged as a promising treatment for melasma; however, few controlled studies exist." | 2.87 | Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma. ( Del Rosario, E; Florez-Pollack, S; Hernandez, K; Hynan, LS; Pandya, AG; Rodrigues, M; Tovar-Garza, A; Zapata, L, 2018) |
| "Tranexamic acid (TA) is a relatively new brightening agent that interferes with keratinocyte-melanocyte interactions." | 2.87 | Comparing the efficacy of topical hydroquinone 2% versus intradermal tranexamic acid microinjections in treating melasma: a split-face controlled trial. ( Darayesh, M; Heiran, A; Saki, N, 2018) |
| "Tranexamic acid (TXA) has been used orally, intravenously, topically and intradermally (microinjection, microneedling) for treating melasma." | 2.84 | Therapeutic efficacy and safety of oral tranexamic acid and that of tranexamic acid local infiltration with microinjections in patients with melasma: a comparative study. ( Chauhan, PS; Mahajan, VK; Mehta, KS; Rawat, R; Sharma, R; Shiny, TN, 2017) |
| "Melasma's high prevalence and profound psychological impact on patients necessitate efficacious, economical, and safe therapeutic interventions." | 2.84 | Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a shor ( Abedini, R; Akbari, Z; Ghayoumi, A; Goodarzi, A; Hedayat, K; Hosseini, H; Lajevardi, V, 2017) |
| "Melasma is a common chronic refractory disorder of pigmentation affecting people with darker skin types." | 2.82 | Melasma treatment: a systematic review. ( Agozzino, M; Conforti, C; Dianzani, C; Marangi, GF; Morariu, SH; Neagu, N; Pellacani, G; Persichetti, P; Piccolo, D; Segreto, F; Zalaudek, I, 2022) |
| "Melasma is a common relapsing hyperpigmentation disorder, which is often difficult to treat." | 2.82 | Platelet-Rich Plasma in Melasma-A Systematic Review. ( Gupta, M; Sarkar, R, 2022) |
| "Melasma is a common malady affecting all races with a higher incidence in Hispanics, Middle Eastern, Asians, and African origin females (Fitzpatrick skin phototypes III-V)." | 2.82 | Medical therapies for melasma. ( Blicharz, L; Galadari, H; Gold, MH; Goldman, MP; Goldust, M; Kassir, M; Konnikov, N; Mahajan, VK; Patil, A, 2022) |
| "Microneedling is an alternative treatment for melasma especially by improving penetration of pharmacological agents into the skin." | 2.82 | Microneedling with cutaneous delivery of topical agents for the treatment of melasma: A systematic review. ( Brasil Dos Santos, J; da Silva E Souza Lorca, B; de Lima, GG; Faria de Freitas, ZM; Miranda Pinheiro, G; Nagem Lopes, LP; Teixeira da Silva, R, 2022) |
| " Furthermore, no serious adverse events were observed, except mild erythema and burning pain." | 2.82 | Efficacy and safety of laser-assisted delivery of tranexamic acid for the treatment of melasma: a systematic review and meta‑analysis. ( Feng, J; Shen, S; Song, X; Xiang, W, 2022) |
| "Tranexamic acid (TNA) is a novel therapeutic agent for hyperpigmented skin disorders." | 2.82 | Topical tranexamic acid as an adjuvant treatment in melasma: Side-by-side comparison clinical study. ( Chung, JY; Lee, JH, 2016) |
| "Melasma is one of the most common cosmetic disorders with skin darkening." | 2.80 | Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma. ( Banihashemi, M; Jaafari, MR; Jabari, A; Salehi, M; Zabolinejad, N, 2015) |
| "Melasma is associated with epidermal hyperpigmentation, weak basement membrane, vascular proliferation and increased numbers of mast cell." | 2.78 | Effect of tranexamic acid on melasma: a clinical trial with histological evaluation. ( Choi, HR; Choi, SY; Kang, HY; Na, JI; Park, KC; Yang, SH, 2013) |
| "Tranexamic acid (TXA) is a novel treatment option for melasma; however, no consensus exists on its use." | 2.72 | Efficacy and safety of tranexamic acid in the treatment of adult melasma: An updated meta-analysis of randomized controlled trials. ( Feng, X; Su, H; Xie, J, 2021) |
| "Oral tranexamic acid is a promising new treatment for moderate and severe recurrent melasma." | 2.66 | Melasma Treatment: An Evidence-Based Review. ( McKesey, J; Pandya, AG; Tovar-Garza, A, 2020) |
| "Melasma is a common acquired disorder of hyperpigmentation, classically manifesting as symmetric brown patches on the face." | 2.66 | The Vascular Component of Melasma: A Systematic Review of Laboratory, Diagnostic, and Therapeutic Evidence. ( Austin, E; Jagdeo, J; Masub, N; Nguyen, JK, 2020) |
| "Tranexamic acid (TXA) is a novel treatment for melasma that has a multimodal mechanism of action." | 2.58 | Oral Tranexamic Acid for the Treatment of Melasma: A Review. ( Bala, HR; Lee, S; Pandya, AG; Rodrigues, M; Wong, C, 2018) |
| "Melasma is a highly prevalent, chronic, and pigmentary disorder." | 2.58 | Tranexamic Acid for Adults with Melasma: A Systematic Review and Meta-Analysis. ( Fang, QQ; Gao, J; Tan, WQ; Wang, XW; Zhang, L; Zhao, QM; Zhao, WY, 2018) |
| "Tranexamic acid is a procoagulant agent that is approved by the US Food and Drug Administration for treatment of menorrhagia and to prevent hemorrhage in patients with hemophilia undergoing tooth extractions." | 2.58 | Treatment of melasma using tranexamic acid: what's known and what's next. ( Sheu, SL, 2018) |
| "Tranexamic acid is a novel treatment option for melasma; however, there is no consensus on its use." | 2.55 | Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review. ( Cho, SH; Kim, HJ; Kim, HS; Lee, JD; Moon, SH, 2017) |
| "Tranexamic acid (TA) is a plasmin inhibitor used to prevent abnormal fibrinolysis to reduce blood loss and exerts its effect by reversibly blocking lysine binding sites on plasminogen molecules, thus inhibiting plasminogen activator (PA) from converting plasminogen to plasmin." | 2.55 | Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies. ( Ehsani, AH; Niknam, S; Taraz, M, 2017) |
| "The review revealed that TA treatment for melasma is equally effective or more effective than other standard therapies and may induce fewer side effects." | 2.55 | Tranexamic Acid in the Treatment of Melasma: A Review of the Literature. ( Alfuraih, A; ALharbi, M; ALOmair, I; Cervantes, J; Eber, AE; Fayne, R; Magno, RJ; Nouri, K; Perper, M; Verne, SH, 2017) |
| "The aim of this study was to assess the effectiveness of photo rejuvenation combined with tranexamic acid and hydroquinone cream in the treatment of complex facial pigmentation." | 1.91 | Efficacy of photorejuvenation combined with tranexamic acid and hydroquinone cream in the treatment of complex facial pigmentation. ( Lin, C; Zhu, X, 2023) |
| " The Physician Global Assessment (PGA) and Patient satisfaction were documented, and adverse reactions were recorded." | 1.91 | Efficacy and safety of the combination of tranexamic acid injection and electro-optical synergy (ELOS) versus tranexamic acid injection alone in the treatment of melasma. ( Duan, J; Tang, L; Wang, L; Wang, Y; Ye, F, 2023) |
| "Tranexamic acid (TXA) was injected intradermally into the right side of the face by using a concentration of 4 mg/ml, while platelet-rich plasma (PRP) was injected intradermally into the left side." | 1.91 | Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study. ( Abd Elraouf, IG; Fouda, I; Obaid, ZM, 2023) |
| "Tranexamic acid (TXA) is a promising therapeutic agent in melasma that can act on multiple pathophysiologic mechanisms of melasma." | 1.91 | Tranexamic acid may promote melanocores clustering in keratinocytes through upregulation of Rab5b. ( Chen, Y; Geng, Q; Guan, C; Hu, Y; Song, X; Xie, B; Xu, J; Zhao, Y, 2023) |
| "Melasma is a common dermatologic condition affecting all skin types." | 1.91 | Assessment of the Efficacy of Tranexamic Acid Solution 5% in the Treatment of Melasma in Patients of South Asian Descent. ( Abbasi, HH; Akhtar, N; Jasti, S; Rao, B; Shah, A; Shah, RR; Sharif, S; Waqas, N, 2023) |
| "Melasma is a complex pigmentary disorder with challenging management." | 1.72 | Dermoscopic evaluation of tranexamic acid versus Vitamin C, with microneedling in the treatment of melasma: a comparative, split-face, single-blinded study. ( Amer, MA; Mostafa, WZ; Tahoun, AI, 2022) |
| "Oral tranexamic acid 250 mg was taken by both groups as a single oral daily dose." | 1.72 | Liposomal azelaic acid 20% cream vs hydroquinone 4% cream as adjuvant to oral tranexamic acid in melasma: a comparative study. ( Akl, EM, 2022) |
| "Tranexamic acid (TA) is a new promising treatment of melasma." | 1.72 | A split face comparative study between intradermal tranexamic acid and Erbium-YAG laser in treatment of melasma. ( Abdallah, N; Agamia, N; Otb, S; Sadek, A; Shaarawy, E; Soliman, M; Tawfik, AA, 2022) |
| " However, due to its hydrophilic structure, topical TA should be combined with a penetration-enhancing strategy to augment efficacy." | 1.72 | Comparison of fractional erbium:YAG laser-assisted tranexamic acid delivery alone and in combination with oral tranexamic acid in melasma. ( Botsali, A; Caliskan, E; Erbil, H; Esme, P, 2022) |
| "Melasma is an acquired melanogenesis dysfunction resulting in chronic hyperpigmentation commonly affecting the face and other frequently sun-exposed areas of the body." | 1.72 | Evaluation of oral tranexamic acid as a novel treatment for melasma with a high benefit-risk ratio. ( Peng, L; Simpson, J; Ting, W, 2022) |
| "Though easily diagnosable, a tangible treatment for melasma still remains elusive." | 1.72 | A comparative evaluation of the efficacy of intralesional tranexamic acid versus platelet rich plasma in the treatment of melasma. ( Bubna, AK; Patil, NK, 2022) |
| "To assess and compare the efficacy of tranexamic acid (TXA) intradermal microinjection alone versus its combination with low-power, low-density fractional CO2 laser in a sequential pattern in melasma." | 1.72 | Tranexamic Acid Microinjection Alone Versus Its Combination With Fractional Carbon Dioxide Laser in Melasma Treatment: A Dermoscopic Evaluation. ( Abdel Hay, RM; Abouelazm, DI; Said, ER; Tawfic, SO, 2022) |
| " It was a split-face study; for 12 weeks, the right side of the face was treated with low fluence Q-switched Nd:YAG laser combined with intradermal injection of tranexamic acid, while the left side was treated with an injection of tranexamic acid intradermal alone." | 1.72 | Split-face comparative study between intradermal tranexamic acid injection alone versus intradermal tranexamic acid injection combined with Q-switched Nd:YAG laser in melasma treatment: dermoscopic and clinical evaluation. ( El-Attar, YA; Hawwam, SA; Ismail, M, 2022) |
| "The pathogenesis of melasma is not fully understood yet and this often causes difficulties in treatment." | 1.72 | Comparison of clinical results of oral tranexamic acid and platelet rich plasma therapies in melasma treatment. ( Polat, Y; Saraç, G, 2022) |
| "4,5 Our case series demonstrates the effectiveness and safety profile of utilizing oral TXA to treat recalcitrant melasma and highlights a possible dosing regimen that can be used for the novel therapy." | 1.72 | Oral Tranexamic Acid for the Treatment of Melasma: A Case Series and Novel Dosing Regimen. ( Bhukhan, A; Foss, M; Nathoo, R; Nethers, K, 2022) |
| "Melasma and vitiligo are both common pigmentary disorders, and the treatment is challenging." | 1.62 | Feasibility of oral tranexamic acid for vitiligo patients with melasma. ( Chiang, PH; Chiu, YC; Chung, WH; Ku, CL; Lin, YJ; Ng, CY, 2021) |
| "Melasma is a disorder of hyperpigmentation that is frustratingly resistant to therapy with a high recurrence rate on treatment discontinuation." | 1.62 | Clinico-epidemiological profile and long term follow up in melasma. ( Bishnoi, A; Kaushik, A; Kumaran, MS; Narayan R, V; Parsad, D; Vinay, K, 2021) |
| " Pharmacokinetics study indicated the bioavailability of dissolving microneedles was more than 1." | 1.62 | Novel dissolving microneedles preparation for synergistic melasma therapy: Combined effects of tranexamic acid and licorice extract. ( Cheng, A; Gao, Y; Liu, H; Wang, B; Wang, X; Xing, M; Zhang, S; Zhao, L; Zhou, Z, 2021) |
| "Melasma is a common acquired disorder of pigmentation." | 1.62 | A comparative study between oral tranexamic acid versus oral tranexamic acid and Q-switched Nd-YAG laser in melasma treatment: a clinical and dermoscopic evaluation. ( Abdallah, W; Agamia, N; Apalla, Z; Salem, W, 2021) |
| "Melasma is an acquired disorder of facial pigmentation which is a treatment challenge." | 1.56 | Melasma: A critical analysis of clinical trials investigating treatment modalities published in the past 10 years. ( Spierings, NMK, 2020) |
| "Melasma is a common pigmentary disorder that responds well to treatment with oral and/or locally injected tranexamic acid but less so to topical application." | 1.56 | In vitro human skin concentrations following topical application of 2% tranexamic acid in co-enhancer cream and branded cream formulations. ( Davis, AF; Marcant, M; Ng, SP, 2020) |
| " TA appears to be a promising therapeutic option in treating melasma with fewer adverse effects, same or even better results in comparison to HQ cream." | 1.56 | Efficacy and safety of tranexamic acid 5% cream vs hydroquinone 4% cream in treating melasma: A split-face comparative clinical, histopathological, and antera 3D camera study. ( El-Husseiny, R; Rakha, N; Sallam, M, 2020) |
| " Future studies are required to further characterize the effects of TXA on the histopathology and immunohistochemistry of melasma, to standardize dosing schedule, duration of treatment and long term outcome, of which there are no definitive guidelines at present." | 1.48 | Efficacy of oral tranexemic acid in refractory melasma: A clinico-immuno-histopathological study. ( Bhattacharjee, R; Kumaran, MS; Nagaraju, D; Parsad, D; Saikia, UN; Vinay, K, 2018) |
| "Tranexamic acid has been found to lighten melasma by interfering with the interaction of melanocytes and keratinocytes by inhibiting the plasminogen/plasmin system." | 1.46 | Oral tranexamic acid lightens refractory melasma. ( Chua, SH; Goh, BK; Sen, P; Tan, AWM, 2017) |
| "Tranexamic acid (TA) has been suggested as an effective treatment for melasma." | 1.43 | Efficacy and possible mechanisms of topical tranexamic acid in melasma. ( Fujiwara, R; Kang, HY; Kim, SJ; Park, JY; Shibata, T, 2016) |
| "Oral tranexamic acid (TA) has emerged as a potential treatment for refractory melasma." | 1.43 | Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. ( Goh, CL; Lee, HC; Thng, TG, 2016) |
| "Tranexamic acid tablets were prescribed at a dosage of 250 mg twice daily for a therapeutic period of 6 months." | 1.38 | Treatment of melasma with oral administration of tranexamic acid. ( Guo, J; Pan, L; Shi, H; Sun, Y; Wu, H; Wu, S; Yan, S, 2012) |
| "Melasma is a common cosmetic problem among Asians." | 1.33 | Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. ( Ahn, KY; Kim, JY; Kim, MY; Lee, JH; Lim, SH; Park, JG; Park, YM, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (1.56) | 29.6817 |
| 2010's | 40 (31.25) | 24.3611 |
| 2020's | 86 (67.19) | 2.80 |
| Authors | Studies |
|---|---|
| Zaky, MS | 1 |
| Obaid, ZM | 2 |
| Khalil, EA | 1 |
| Elsaie, ML | 1 |
| Kumaran, MS | 3 |
| Narayan R, V | 1 |
| Kaushik, A | 1 |
| Bishnoi, A | 2 |
| Vinay, K | 3 |
| Parsad, D | 3 |
| Debasmita, B | 1 |
| Raj, C | 1 |
| Ishan, A | 1 |
| Ipsita, D | 1 |
| El Attar, Y | 1 |
| Doghaim, N | 1 |
| El Far, N | 1 |
| El Hedody, S | 1 |
| Hawwam, SA | 2 |
| Behrangi, E | 1 |
| Shemshadi, M | 1 |
| Ghassemi, M | 1 |
| Goodarzi, A | 2 |
| Dilmaghani, S | 1 |
| Khalili, M | 1 |
| Amiri, R | 1 |
| Iranmanesh, B | 1 |
| Zartab, H | 1 |
| Aflatoonian, M | 2 |
| Sarkar, R | 1 |
| Gupta, M | 1 |
| Park, SJ | 1 |
| Park, JW | 1 |
| Seo, SJ | 1 |
| Park, KY | 1 |
| Ismail, M | 1 |
| El-Attar, YA | 1 |
| Perveen, S | 1 |
| Rubin, A | 1 |
| Berger, L | 1 |
| Xiong, W | 1 |
| Waqas, N | 2 |
| Sharif, S | 2 |
| Rao, B | 2 |
| Kim, KM | 1 |
| Lim, HW | 1 |
| Tawfic, SO | 2 |
| Abdel Hay, RM | 1 |
| Abouelazm, DI | 1 |
| Said, ER | 1 |
| Martinez-Rico, JC | 1 |
| Chavez-Alvarez, S | 1 |
| Herz-Ruelas, ME | 1 |
| Sosa-Colunga, SA | 1 |
| Ocampo-Candiani, J | 1 |
| Suro-Santos, Y | 1 |
| Vazquez Martinez, O | 1 |
| Botsali, A | 1 |
| Esme, P | 1 |
| Erbil, H | 1 |
| Caliskan, E | 1 |
| Foss, M | 1 |
| Nethers, K | 1 |
| Bhukhan, A | 1 |
| Nathoo, R | 1 |
| Polat, Y | 1 |
| Saraç, G | 1 |
| Patil, NK | 1 |
| Bubna, AK | 1 |
| Li, Y | 3 |
| Yao, C | 1 |
| Zhang, H | 1 |
| Li, L | 2 |
| Song, Y | 1 |
| Wang, JV | 2 |
| Valiga, A | 1 |
| Geronemus, RG | 3 |
| Mahajan, VK | 3 |
| Patil, A | 1 |
| Blicharz, L | 1 |
| Kassir, M | 1 |
| Konnikov, N | 1 |
| Gold, MH | 1 |
| Goldman, MP | 1 |
| Galadari, H | 1 |
| Goldust, M | 1 |
| Brasil Dos Santos, J | 1 |
| Nagem Lopes, LP | 1 |
| de Lima, GG | 1 |
| Teixeira da Silva, R | 1 |
| da Silva E Souza Lorca, B | 1 |
| Miranda Pinheiro, G | 1 |
| Faria de Freitas, ZM | 1 |
| Simpson, J | 1 |
| Peng, L | 1 |
| Ting, W | 1 |
| Chevala, NT | 1 |
| Dsouza, JA | 1 |
| Saini, H | 1 |
| Kumar, L | 1 |
| Feng, J | 3 |
| Shen, S | 3 |
| Song, X | 4 |
| Xiang, W | 3 |
| Chang, YF | 1 |
| Lee, TL | 1 |
| Oyerinde, O | 1 |
| Desai, SR | 1 |
| Aljabban, A | 1 |
| Bay, CP | 1 |
| Bain, PA | 1 |
| Chung, HJ | 1 |
| Mahjoub, TT | 1 |
| Milibary, HH | 1 |
| Konisky, H | 1 |
| Balazic, E | 1 |
| Jaller, JA | 1 |
| Khanna, U | 1 |
| Kobets, K | 1 |
| Poostiyan, N | 1 |
| Alizadeh, M | 1 |
| Shahmoradi, Z | 1 |
| Fatemi Naeini, F | 1 |
| Jia, Z | 1 |
| Tian, K | 1 |
| Zhong, Y | 1 |
| Wang, X | 3 |
| Gao, S | 1 |
| Xu, W | 1 |
| Li, K | 1 |
| Wu, L | 1 |
| Bhattacharjee, R | 2 |
| Hanumanthu, V | 1 |
| Thakur, V | 1 |
| Kumar, A | 1 |
| Hu, Y | 1 |
| Chen, Y | 1 |
| Zhao, Y | 1 |
| Geng, Q | 1 |
| Guan, C | 1 |
| Xu, J | 1 |
| Xie, B | 1 |
| Abd Elraouf, IG | 1 |
| Fouda, I | 1 |
| Mehmood, M | 1 |
| Ali, M | 1 |
| Saleem, MA | 1 |
| Asghar, S | 1 |
| Hussain, MT | 1 |
| Mehmood, A | 1 |
| Desai, S | 1 |
| Chan, L | 1 |
| Handog, E | 1 |
| Djojoseputro, L | 1 |
| Lim, J | 1 |
| Ling, R | 1 |
| Nguyen, H | 1 |
| Tam, E | 1 |
| Tang, J | 1 |
| Thng, S | 1 |
| Tran, H | 1 |
| Wang, M | 1 |
| Yang, C | 1 |
| Ding, Y | 1 |
| Xu, Z | 3 |
| Xiang, LF | 1 |
| Zhang, C | 3 |
| Galache, TR | 1 |
| Galache, M | 1 |
| Sena, MM | 1 |
| Pavani, C | 1 |
| Wang, Y | 1 |
| Tang, L | 1 |
| Duan, J | 1 |
| Wang, L | 1 |
| Ye, F | 1 |
| Lin, C | 1 |
| Zhu, X | 1 |
| Akhtar, N | 1 |
| Shah, RR | 1 |
| Jasti, S | 1 |
| Shah, A | 1 |
| Abbasi, HH | 1 |
| Zhao, H | 1 |
| Li, M | 1 |
| Zhang, X | 1 |
| Yan, Y | 2 |
| Wang, B | 2 |
| Spierings, NMK | 1 |
| Forbat, E | 1 |
| Al-Niaimi, F | 2 |
| Ali, FR | 3 |
| McKesey, J | 1 |
| Tovar-Garza, A | 3 |
| Pandya, AG | 4 |
| Agamia, N | 2 |
| Apalla, Z | 1 |
| Salem, W | 1 |
| Abdallah, W | 1 |
| Ng, SP | 1 |
| Marcant, M | 1 |
| Davis, AF | 1 |
| Cassiano, D | 1 |
| Esposito, ACC | 1 |
| Hassun, K | 1 |
| Bagatin, E | 1 |
| Lima, MMDA | 1 |
| Lima, EVA | 1 |
| Miot, LDB | 1 |
| Miot, HA | 1 |
| Shihab, N | 1 |
| Prihartono, J | 1 |
| Agustin, T | 1 |
| Legiawati, L | 1 |
| Arreola Jauregui, IE | 1 |
| Huerta Rivera, G | 1 |
| Soria Orozco, M | 1 |
| Meyer-Nava, S | 1 |
| Paniagua Santos, JE | 1 |
| López Zaldo, JB | 1 |
| Meyer-Nava, I | 1 |
| Madrid Carrillo, C | 1 |
| Zaldo Rolón, IE | 1 |
| Baeza Echeverría, AE | 1 |
| Vázquez Huerta, M | 1 |
| Fioranelli, M | 1 |
| Jafferany, M | 1 |
| Wollina, U | 1 |
| Tirant, M | 1 |
| Van Thuong, N | 1 |
| Lotti, T | 1 |
| Sahu, PJ | 1 |
| Singh, AL | 1 |
| Kulkarni, S | 1 |
| Madke, B | 1 |
| Saoji, V | 1 |
| Jawade, S | 1 |
| Chowdhary, B | 1 |
| Mehta, KS | 2 |
| Chauhan, PS | 2 |
| Sharma, V | 1 |
| Sharma, A | 1 |
| Vashist, S | 1 |
| Kumar, P | 1 |
| Litaiem, N | 1 |
| Daadaa, N | 1 |
| Karray, M | 1 |
| Chamli, A | 1 |
| Zeglaoui, F | 1 |
| Shamsi Meymandi, S | 1 |
| Mozayyeni, A | 1 |
| Shamsi Meymandi, M | 1 |
| Otb, S | 1 |
| Shaarawy, E | 1 |
| Sadek, A | 2 |
| Abdallah, N | 1 |
| Soliman, M | 1 |
| Tawfik, AA | 1 |
| Wanitphakdeedecha, R | 1 |
| Sy-Alvarado, F | 1 |
| Patthamalai, P | 1 |
| Techapichetvanich, T | 1 |
| Eimpunth, S | 1 |
| Manuskiatti, W | 1 |
| Mekawy, KMM | 1 |
| Seddeik Abdel-Hameed, AK | 1 |
| Minni, K | 1 |
| Poojary, S | 1 |
| Gamea, MM | 1 |
| Kamal, DA | 1 |
| Donia, AA | 1 |
| Hegab, DS | 1 |
| Sayed, KS | 1 |
| Tuqan, S | 1 |
| Hilal, RF | 1 |
| Ebrahim, HM | 1 |
| Said Abdelshafy, A | 1 |
| Khattab, F | 1 |
| Gharib, K | 1 |
| Kaur, A | 1 |
| Bhalla, M | 1 |
| Pal Thami, G | 1 |
| Sandhu, J | 1 |
| El-Husseiny, R | 1 |
| Rakha, N | 1 |
| Sallam, M | 1 |
| Karrabi, M | 1 |
| Mansournia, MA | 1 |
| Sharestanaki, E | 1 |
| Abdollahnejad, Y | 1 |
| Sahebkar, M | 1 |
| Xing, X | 2 |
| Chen, L | 2 |
| Jin, S | 1 |
| Xiang, L | 1 |
| Nguyen, J | 1 |
| Rajgopal Bala, H | 1 |
| Ross, A | 1 |
| Wong, CC | 1 |
| Paul, E | 1 |
| Rodrigues, M | 3 |
| Pomerantz, H | 1 |
| Christman, MP | 2 |
| Bloom, BS | 1 |
| Lederhandler, M | 1 |
| Feng, H | 2 |
| Holmes, J | 1 |
| Ferzli, G | 1 |
| Jeon, H | 1 |
| Masub, N | 1 |
| Nguyen, JK | 1 |
| Austin, E | 1 |
| Jagdeo, J | 1 |
| Tahoun, AI | 1 |
| Mostafa, WZ | 1 |
| Amer, MA | 1 |
| Qu, Y | 1 |
| Wang, F | 1 |
| Liu, J | 1 |
| Xia, X | 1 |
| El Hadidi, H | 1 |
| Mosaad, R | 1 |
| Ragab, N | 1 |
| Lindgren, AL | 1 |
| Austin, AH | 1 |
| Welsh, KM | 1 |
| Xing, M | 1 |
| Zhao, L | 1 |
| Zhou, Z | 1 |
| Liu, H | 1 |
| Cheng, A | 1 |
| Zhang, S | 1 |
| Gao, Y | 1 |
| Badran, AY | 1 |
| Ali, AU | 1 |
| Gomaa, AS | 1 |
| Akl, EM | 1 |
| Elkamshoushi, AM | 1 |
| Romisy, D | 1 |
| Omar, SS | 1 |
| Neagu, N | 1 |
| Conforti, C | 1 |
| Agozzino, M | 1 |
| Marangi, GF | 1 |
| Morariu, SH | 1 |
| Pellacani, G | 1 |
| Persichetti, P | 1 |
| Piccolo, D | 1 |
| Segreto, F | 1 |
| Zalaudek, I | 1 |
| Dianzani, C | 1 |
| Bailey, AJM | 1 |
| Li, HO | 1 |
| Tan, MG | 1 |
| Cheng, W | 1 |
| Dover, JS | 1 |
| Feng, X | 1 |
| Su, H | 1 |
| Xie, J | 1 |
| Mumtaz, M | 1 |
| Chandio, TH | 1 |
| Shahzad, MK | 1 |
| Hanif, N | 1 |
| Anwar, S | 1 |
| Rafique, S | 1 |
| Kuster Kaminski Arida, D | 1 |
| Orso Rebellato, PR | 1 |
| Marioto de Campos, GL | 1 |
| Costa, A | 1 |
| Vilaverde Schmitt, J | 1 |
| Larocca Skare, T | 1 |
| Rodrigues Lisboa Faucz, L | 1 |
| Chiang, PH | 1 |
| Lin, YJ | 1 |
| Chiu, YC | 1 |
| Chung, WH | 1 |
| Ku, CL | 1 |
| Ng, CY | 1 |
| Mokhtari, F | 1 |
| Bahrami, B | 1 |
| Faghihi, G | 1 |
| Asilian, A | 1 |
| Iraji, F | 1 |
| Sahu, P | 1 |
| Dayal, S | 1 |
| Bhardwaj, N | 1 |
| Kim, HJ | 1 |
| Moon, SH | 1 |
| Cho, SH | 1 |
| Lee, JD | 1 |
| Kim, HS | 1 |
| Xu, Y | 1 |
| Ma, R | 1 |
| Juliandri, J | 1 |
| Xu, B | 1 |
| Wang, D | 1 |
| Lu, Y | 1 |
| Zhou, B | 1 |
| Luo, D | 1 |
| Sharma, R | 1 |
| Rawat, R | 1 |
| Shiny, TN | 1 |
| Cho, YH | 1 |
| Park, JE | 1 |
| Lim, DS | 1 |
| Lee, JS | 1 |
| Del Rosario, E | 1 |
| Florez-Pollack, S | 1 |
| Zapata, L | 1 |
| Hernandez, K | 1 |
| Hynan, LS | 1 |
| Saki, N | 1 |
| Darayesh, M | 1 |
| Heiran, A | 1 |
| Cohen, PR | 2 |
| Laothaworn, V | 1 |
| Juntongjin, P | 1 |
| Sheu, SL | 1 |
| Bala, HR | 1 |
| Lee, S | 1 |
| Wong, C | 1 |
| Nagaraju, D | 1 |
| Saikia, UN | 1 |
| Flora Xiang, L | 1 |
| Abdel Halim, DM | 1 |
| Albarbary, A | 1 |
| Abdelhady, M | 1 |
| Zhang, L | 1 |
| Tan, WQ | 1 |
| Fang, QQ | 1 |
| Zhao, WY | 1 |
| Zhao, QM | 1 |
| Gao, J | 1 |
| Wang, XW | 1 |
| Raimbault, C | 1 |
| Feng, C | 1 |
| Yan, M | 1 |
| Zhu, CY | 1 |
| Sun, QN | 1 |
| Takada, A | 1 |
| Kawada, A | 2 |
| Zubair, R | 1 |
| Lyons, AB | 1 |
| Vellaichamy, G | 1 |
| Peacock, A | 1 |
| Hamzavi, I | 1 |
| Malik, F | 1 |
| Hanif, MM | 1 |
| Mustafa, G | 1 |
| Wohltmann, W | 1 |
| Tse, TW | 1 |
| Hui, E | 1 |
| Sun, Q | 1 |
| He, Z | 1 |
| Fu, L | 1 |
| He, C | 1 |
| Banihashemi, M | 1 |
| Zabolinejad, N | 1 |
| Jaafari, MR | 1 |
| Salehi, M | 1 |
| Jabari, A | 1 |
| Chung, JY | 1 |
| Lee, JH | 4 |
| Bagherani, N | 1 |
| Smoller, BR | 1 |
| Kim, SJ | 1 |
| Park, JY | 1 |
| Shibata, T | 1 |
| Fujiwara, R | 1 |
| Kang, HY | 2 |
| Tan, AWM | 1 |
| Sen, P | 1 |
| Chua, SH | 1 |
| Goh, BK | 1 |
| Lee, HC | 1 |
| Thng, TG | 1 |
| Goh, CL | 1 |
| Kwon, HH | 1 |
| Ohn, J | 1 |
| Suh, DH | 1 |
| Park, HY | 1 |
| Choi, SC | 1 |
| Jung, JY | 1 |
| Kwon, IH | 1 |
| Park, GH | 1 |
| Lajevardi, V | 1 |
| Ghayoumi, A | 1 |
| Abedini, R | 1 |
| Hosseini, H | 1 |
| Akbari, Z | 1 |
| Hedayat, K | 1 |
| Chae, JB | 1 |
| Yang, SH | 2 |
| Byun, SY | 1 |
| Choi, HR | 2 |
| Shin, JW | 1 |
| Park, KC | 2 |
| Taraz, M | 1 |
| Niknam, S | 1 |
| Ehsani, AH | 1 |
| Zhou, LL | 1 |
| Baibergenova, A | 1 |
| Perper, M | 1 |
| Eber, AE | 1 |
| Fayne, R | 1 |
| Verne, SH | 1 |
| Magno, RJ | 1 |
| Cervantes, J | 1 |
| ALharbi, M | 1 |
| ALOmair, I | 1 |
| Alfuraih, A | 1 |
| Nouri, K | 1 |
| Cho, HH | 1 |
| Choi, M | 1 |
| Cho, S | 1 |
| Na, JI | 1 |
| Choi, SY | 1 |
| Kanechorn Na Ayuthaya, P | 1 |
| Niumphradit, N | 1 |
| Manosroi, A | 1 |
| Nakakes, A | 1 |
| Wu, S | 1 |
| Shi, H | 1 |
| Wu, H | 1 |
| Yan, S | 1 |
| Guo, J | 1 |
| Sun, Y | 1 |
| Pan, L | 1 |
| Park, JG | 1 |
| Lim, SH | 1 |
| Kim, JY | 1 |
| Ahn, KY | 1 |
| Kim, MY | 1 |
| Park, YM | 1 |
| Konishi, N | 1 |
| Morimoto, Y | 1 |
| Watake, A | 1 |
| Matsuda, H | 1 |
| Oiso, N | 1 |
| Kawara, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effectiveness of 3% Topical Tranexamic Acid Compared to 4% Topical Hydroquinone as Therapy of Melasma[NCT06010810] | Phase 3 | 20 participants (Anticipated) | Interventional | 2023-06-01 | Active, not recruiting | ||
| Efficacy and Safety of Topical Cysteamine for Postinflammatory Hyperpigmentation: A Randomized Control, Double Blinded-trial[NCT05206318] | 40 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | |||
| RFMN in Combination With 1927 nm Thulium Laser for Treating Photoaged Skin: a Prospective, Controlled Study[NCT06029725] | 35 participants (Anticipated) | Interventional | 2023-10-15 | Not yet recruiting | |||
| Comparing Tranexamic Acid Microinjection Alone Versus Its Combination With Fractional Carbon Dioxide Laser in Melasma Treatment[NCT03899233] | Phase 4 | 25 participants (Anticipated) | Interventional | 2019-04-01 | Not yet recruiting | ||
| The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans[NCT04233749] | Phase 2 | 5 participants (Anticipated) | Interventional | 2020-03-17 | Recruiting | ||
| Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris[NCT03361345] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2018-11-01 | Withdrawn (stopped due to Lack of recruitment) | ||
| Tissue-resident Memory T Cells Expression in Melasma[NCT05698342] | 20 participants (Actual) | Observational | 2021-07-01 | Completed | |||
| Different Dermatological Approaches in Treatment of Melasma: A Split Face Randomized Clinical Trial[NCT03923062] | Phase 4 | 40 participants (Anticipated) | Interventional | 2020-02-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
27 reviews available for tranexamic acid and Chloasma
| Article | Year |
|---|---|
Safety and efficacy of mesotherapy in the treatment of melasma: A review article.
Topics: Ascorbic Acid; Chemexfoliation; Humans; Melanosis; Mesotherapy; Tranexamic Acid; Treatment Outcome | 2022 |
Platelet-Rich Plasma in Melasma-A Systematic Review.
Topics: Administration, Cutaneous; Blood Transfusion, Autologous; Combined Modality Therapy; Humans; Melanin | 2022 |
The uses of tranexamic acid in dermatology: a review.
Topics: Antifibrinolytic Agents; COVID-19; Dermatology; Humans; Melanosis; Pandemics; Tranexamic Acid; Treat | 2023 |
Medical therapies for melasma.
Topics: Adrenal Cortex Hormones; Cosmeceuticals; Female; Fluocinolone Acetonide; Humans; Hydroquinones; Male | 2022 |
Microneedling with cutaneous delivery of topical agents for the treatment of melasma: A systematic review.
Topics: Administration, Cutaneous; Adult; Combined Modality Therapy; Female; Humans; Hyperpigmentation; Male | 2022 |
Efficacy and safety of laser-assisted delivery of tranexamic acid for the treatment of melasma: a systematic review and meta‑analysis.
Topics: Drug Delivery Systems; Humans; Lasers; Melanosis; Skin; Tranexamic Acid | 2022 |
Efficacy and safety of laser-assisted delivery of tranexamic acid for the treatment of melasma: a systematic review and meta‑analysis.
Topics: Drug Delivery Systems; Humans; Lasers; Melanosis; Skin; Tranexamic Acid | 2022 |
Efficacy and safety of laser-assisted delivery of tranexamic acid for the treatment of melasma: a systematic review and meta‑analysis.
Topics: Drug Delivery Systems; Humans; Lasers; Melanosis; Skin; Tranexamic Acid | 2022 |
Efficacy and safety of laser-assisted delivery of tranexamic acid for the treatment of melasma: a systematic review and meta‑analysis.
Topics: Drug Delivery Systems; Humans; Lasers; Melanosis; Skin; Tranexamic Acid | 2022 |
Efficacy and safety of laser-assisted delivery of tranexamic acid for the treatment of melasma: a systematic review and meta‑analysis.
Topics: Drug Delivery Systems; Humans; Lasers; Melanosis; Skin; Tranexamic Acid | 2022 |
Efficacy and safety of laser-assisted delivery of tranexamic acid for the treatment of melasma: a systematic review and meta‑analysis.
Topics: Drug Delivery Systems; Humans; Lasers; Melanosis; Skin; Tranexamic Acid | 2022 |
Efficacy and safety of laser-assisted delivery of tranexamic acid for the treatment of melasma: a systematic review and meta‑analysis.
Topics: Drug Delivery Systems; Humans; Lasers; Melanosis; Skin; Tranexamic Acid | 2022 |
Efficacy and safety of laser-assisted delivery of tranexamic acid for the treatment of melasma: a systematic review and meta‑analysis.
Topics: Drug Delivery Systems; Humans; Lasers; Melanosis; Skin; Tranexamic Acid | 2022 |
Efficacy and safety of laser-assisted delivery of tranexamic acid for the treatment of melasma: a systematic review and meta‑analysis.
Topics: Drug Delivery Systems; Humans; Lasers; Melanosis; Skin; Tranexamic Acid | 2022 |
Efficacy and safety of topical agents in the treatment of melasma: What's evidence? A systematic review and meta-analysis.
Topics: Cysteamine; Humans; Melanosis; Tranexamic Acid; Treatment Outcome; Zinc Sulfate | 2023 |
Oral tranexamic acid in the treatment of hyperpigmentation disorder beyond melasma: A review.
Topics: Antifibrinolytic Agents; Humans; Hyperpigmentation; Lichen Planus; Melanosis; Tranexamic Acid; Treat | 2023 |
Tranexamic acid in melasma: A focused review on drug administration routes.
Topics: Administration, Topical; Adult; Female; Humans; Hydroquinones; Melanosis; Tranexamic Acid; Treatment | 2023 |
Optimizing Melasma Management With Topical Tranexamic Acid: An Expert Consensus.
Topics: Administration, Topical; Consensus; Humans; Melanosis; Tranexamic Acid; Treatment Outcome | 2023 |
Unveiling the mystery of Riehl's melanosis: An update from pathogenesis, diagnosis to treatment.
Topics: Glycyrrhizic Acid; Humans; Melanosis; Skin; Tranexamic Acid; Treatment Outcome; Ultraviolet Rays | 2023 |
The emerging importance of tranexamic acid in dermatology.
Topics: Angioedema; Antifibrinolytic Agents; Dermatology; Hemorrhage; Humans; Melanosis; Pigmentation Disord | 2020 |
Melasma Treatment: An Evidence-Based Review.
Topics: Chemexfoliation; Humans; Laser Therapy; Melanosis; Retinoids; Skin Lightening Preparations; Tranexam | 2020 |
The Vascular Component of Melasma: A Systematic Review of Laboratory, Diagnostic, and Therapeutic Evidence.
Topics: Administration, Cutaneous; Administration, Oral; Angiogenesis Inhibitors; Dermoscopy; Humans; Lasers | 2020 |
Melasma treatment: a systematic review.
Topics: Administration, Cutaneous; Humans; Melanosis; Quality of Life; Tranexamic Acid; Treatment Outcome | 2022 |
Microneedling as an adjuvant to topical therapies for melasma: A systematic review and meta-analysis.
Topics: Administration, Cutaneous; Ascorbic Acid; Humans; Melanosis; Prospective Studies; Tranexamic Acid; T | 2022 |
Efficacy and safety of tranexamic acid in the treatment of adult melasma: An updated meta-analysis of randomized controlled trials.
Topics: Drug Administration Routes; Humans; Melanosis; Randomized Controlled Trials as Topic; Tranexamic Aci | 2021 |
Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review.
Topics: Chi-Square Distribution; Dermatologic Agents; Humans; Keratinocytes; Melanins; Melanocytes; Melanosi | 2017 |
Treatment of melasma using tranexamic acid: what's known and what's next.
Topics: Administration, Cutaneous; Administration, Oral; Dermatologic Agents; Humans; Melanosis; Tranexamic | 2018 |
Oral Tranexamic Acid for the Treatment of Melasma: A Review.
Topics: Administration, Oral; Ascorbic Acid; Dermatologic Agents; Evidence-Based Medicine; Humans; Melanosis | 2018 |
Tranexamic Acid for Adults with Melasma: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Adult; Case-Control Studies; Erythema; Humans; Melanins; Melanosis; Middle Aged; Publica | 2018 |
[What's new in interventional dermatology?]
Topics: Blindness; Botulinum Toxins, Type A; Cicatrix, Hypertrophic; Dermal Fillers; Dermatology; Embolism; | 2018 |
What's New in Pigmentary Disorders.
Topics: alpha-MSH; Antifibrinolytic Agents; Bimatoprost; Dermatologic Agents; Humans; Hydroquinones; Inflamm | 2019 |
Tranexamic acid: an important adjuvant in the treatment of melasma.
Topics: Administration, Oral; Ascorbic Acid; Dermatologic Agents; Drug Therapy, Combination; Humans; Melanos | 2013 |
Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies.
Topics: Administration, Cutaneous; Administration, Oral; Antifibrinolytic Agents; Dermatologic Agents; Human | 2017 |
Melasma: systematic review of the systemic treatments.
Topics: Administration, Oral; Antifibrinolytic Agents; Antioxidants; Biflavonoids; Carotenoids; Catechin; Di | 2017 |
Tranexamic Acid in the Treatment of Melasma: A Review of the Literature.
Topics: Administration, Cutaneous; Administration, Oral; Antifibrinolytic Agents; Dermatologic Agents; Femal | 2017 |
50 trials available for tranexamic acid and Chloasma
| Article | Year |
|---|---|
Microneedling-assisted topical tranexamic acid solution versus 4% hydroquinone for treating melasma: A split-face randomized study.
Topics: Female; Humans; Hydroquinones; Melanosis; Tranexamic Acid; Treatment Outcome | 2021 |
A prospective randomized controlled trial of Q-switched Nd:YAG laser with topical 3% tranexamic acid (TA) versus microneedling with topical 3% tranexamic acid (TA) in treatment of melasma.
Topics: Erythema; Humans; Lasers, Solid-State; Melanosis; Prospective Studies; Tranexamic Acid; Treatment Ou | 2022 |
Efficacy and Safety of tranexamic acid versus vitamin c after microneedling in treatment of melasma: Clinical and Dermoscopic study.
Topics: Administration, Cutaneous; Ascorbic Acid; Humans; Melanosis; Prospective Studies; Tranexamic Acid; T | 2022 |
Comparison of efficacy and safety of tranexamic acid mesotherapy versus oral tranexamic acid in patients with melasma undergoing Q-switched fractional 1064-nm Nd:YAG laser: A blinded RCT and follow-up.
Topics: Follow-Up Studies; Humans; Lasers, Solid-State; Melanosis; Mesotherapy; Prospective Studies; Tranexa | 2022 |
Evaluating the tolerance and efficacy of laser-assisted delivery of tranexamic acid, niacinamide, and kojic acid for melasma: A single center, prospective, split-face trial.
Topics: Humans; Lasers, Solid-State; Melanosis; Niacinamide; Prospective Studies; Pyrones; Tranexamic Acid; | 2022 |
A Randomized Trial of Oral Tranexamic Acid With Fluocinolone-Based Triple Cream Versus Fluocinolone Based Triple Cream Alone for the Treatment of Melasma.
Topics: Fluocinolone Acetonide; Humans; Hyperpigmentation; Melanosis; Tranexamic Acid; Treatment Outcome | 2022 |
Oral tranexamic acid with a triple combination cream versus oral tranexamic acid monotherapy in the treatment of severe melasma.
Topics: Combined Modality Therapy; Emollients; Female; Humans; Melanins; Melanosis; Tranexamic Acid; Treatme | 2022 |
Efficacy and safety of 755-nm picosecond alexandrite laser with topical tranexamic acid versus laser monotherapy for melasma and facial rejuvenation: a multicenter, randomized, double-blinded, split-face study in Chinese patients.
Topics: China; Humans; Lasers, Solid-State; Melanosis; Rejuvenation; Tranexamic Acid; Treatment Outcome | 2022 |
Tranexamic acid microinjections versus tranexamic acid mesoneedling in the treatment of facial melasma: A randomized assessor-blind split-face controlled trial.
Topics: Adult; Female; Humans; Hyperpigmentation; Male; Melanosis; Microinjections; Middle Aged; Tranexamic | 2023 |
Effectiveness of combination therapy of broadband light and intradermal injection of tranexamic acid in the treatment of chloasma.
Topics: Combined Modality Therapy; Female; Humans; Injections, Intradermal; Melanosis; Tranexamic Acid; Trea | 2023 |
A randomized, open-label study to compare two different dosing regimens of oral tranexamic acid in treatment of moderate to severe facial melasma.
Topics: Administration, Oral; Adult; Humans; Melanosis; Middle Aged; Quality of Life; Recurrence; Tranexamic | 2023 |
Comment on article by Poostiyan et al.: Tranexamic acid microinjections versus tranexamic acid mesoneedling in the treatment of facial melasma: A randomized assessor-blind split-face controlled trial.
Topics: Administration, Cutaneous; Antifibrinolytic Agents; Humans; Melanosis; Microinjections; Tranexamic A | 2023 |
Amber photobiomodulation versus tranexamic acid for the treatment of melasma: protocol for a double-blind, randomised controlled trial.
Topics: Amber; Brazil; Double-Blind Method; Female; Humans; Melanosis; Quality of Life; Randomized Controlle | 2023 |
Comparing the efficacy of Myjet-assisted tranexamic acid and vitamin C in treating melasma: A split-face controlled trial.
Topics: Adult; Ascorbic Acid; Drug Therapy, Combination; Face; Female; Humans; Image Processing, Computer-As | 2020 |
Efficacy and safety of microneedling and oral tranexamic acid in the treatment of facial melasma in women: An open, evaluator-blinded, randomized clinical trial.
Topics: Adult; Aged; Alopecia; Combined Modality Therapy; Dry Needling; Female; Herpes Simplex; Humans; Mela | 2020 |
Randomised, controlled, double-blind study of combination therapy of oral tranexamic acid and topical hydroquinone in the treatment of melasma.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Antifibrinolytic Agents; Double-Blind Method | 2020 |
New local treatments for different types of melasma: Vascular type vs nonvascular type. A randomized polycentric study.
Topics: Administration, Cutaneous; Humans; Melanosis; Severity of Illness Index; Skin Cream; Tranexamic Acid | 2020 |
Study of oral tranexamic acid, topical tranexamic acid, and modified Kligman's regimen in treatment of melasma.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Drug Combinations; Female; Fluoc | 2020 |
Therapeutic efficacy and safety of oral tranexamic acid 250 mg once a day versus 500 mg twice a day: a comparative study.
Topics: Administration, Oral; Adolescent; Adult; Cross-Sectional Studies; Dose-Response Relationship, Drug; | 2021 |
Efficacy of microneedling plus topical 4% tranexamic acid solution vs 4% hydroquinone in the treatment of melasma: A single-blind randomized clinical trial.
Topics: Administration, Cutaneous; Female; Humans; Hydroquinones; Melanosis; Single-Blind Method; Tranexamic | 2020 |
The efficacy in treatment of facial melasma with thulium 1927-nm fractional laser-assisted topical tranexamic acid delivery: a split-face, double-blind, randomized controlled pilot study.
Topics: Adult; Aged; Combined Modality Therapy; Double-Blind Method; Female; Humans; Lasers; Male; Melanins; | 2020 |
Efficacy and safety of oral tranexamic acid as an adjuvant in Indian patients with melasma: a prospective, interventional, single-centre, triple-blind, randomized, placebo-control, parallel group study.
Topics: Asian People; Humans; Melanosis; Prospective Studies; Tranexamic Acid; Tretinoin | 2020 |
Comparative study between topical tranexamic acid alone versus its combination with autologous platelet rich plasma for treatment of melasma.
Topics: Administration, Cutaneous; Female; Humans; Melanosis; Platelet-Rich Plasma; Tranexamic Acid; Treatme | 2022 |
Q-Switched Nd:YAG (532 nm) Laser Versus Intra-Dermal Tranexamic Acid for Treatment of Facial Ephelides: A Split Face, Randomized, Comparative Trial.
Topics: Female; Humans; Hyperpigmentation; Lasers, Solid-State; Melanosis; Tranexamic Acid; Treatment Outcom | 2021 |
Tranexamic Acid for Melasma Treatment: A Split-Face Study.
Topics: Administration, Cutaneous; Adult; Antifibrinolytic Agents; Combined Modality Therapy; Dry Needling; | 2020 |
Clinical Efficacy of Topical Tranexamic Acid With Microneedling in Melasma.
Topics: Administration, Cutaneous; Adult; Antifibrinolytic Agents; Combined Modality Therapy; Dry Needling; | 2020 |
Clinical evaluation of efficacy and tolerability of cysteamine 5% cream in comparison with tranexamic acid mesotherapy in subjects with melasma: a single-blind, randomized clinical trial study.
Topics: Administration, Cutaneous; Adolescent; Adult; Cysteamine; Female; Humans; Male; Melanosis; Mesothera | 2021 |
The efficacy and safety of topical tranexamic acid (liposomal or lotion with microneedling) versus conventional hydroquinone in the treatment of melasma.
Topics: Administration, Cutaneous; Humans; Hydroquinones; Melanosis; Tranexamic Acid; Treatment Outcome | 2020 |
Effect of oral tranexamic acid on erythema index in patients with melasma.
Topics: Administration, Oral; Adult; Dermatologic Agents; Erythema; Humans; Melanosis; Middle Aged; Severity | 2021 |
Clinical observation and dermoscopy evaluation of fractional CO
Topics: Carbon Dioxide; Dermoscopy; Female; Humans; Lasers, Gas; Melanosis; Tranexamic Acid; Treatment Outco | 2021 |
The efficacy of oral vs different dilutions of intradermal tranexamic acid microinjections in melasma-A randomized clinical trial.
Topics: Administration, Cutaneous; Erythema; Female; Humans; Melanosis; Microinjections; Tranexamic Acid; Tr | 2021 |
Efficacy of topical versus intradermal injection of Tranexamic Acid In Egyptian melasma Patients: A randomised clinical trial.
Topics: Administration, Cutaneous; Adult; Antifibrinolytic Agents; Egypt; Female; Humans; Injections, Intrad | 2021 |
Oral tranexamic acid, hydroquinone 4% and low-fluence 1064 nm Q-switched Nd:YAG laser for mixed melasma: Clinical and dermoscopic evaluation.
Topics: Administration, Oral; Combined Modality Therapy; Humans; Hydroquinones; Hyperpigmentation; Lasers, S | 2022 |
Comparing the Efficacy of Patelet-rich Plasma (PRP) versus Tranexamic Acid (4mg/mL) as Intradermal Treatments of Melasma.
Topics: Administration, Cutaneous; Adult; Humans; Male; Melanosis; Platelet-Rich Plasma; Severity of Illness | 2021 |
Randomized, double-blind, placebo-controlled split-face trial of the efficacy of tranexamic acid by drug delivery through microneedling in the treatment of melasma.
Topics: Administration, Cutaneous; Double-Blind Method; Humans; Melanosis; Pharmaceutical Preparations; Tran | 2021 |
Fractional erbium:YAG laser (2940 nm) plus topical hydroquinone compared to intradermal tranexamic acid plus topical hydroquinone for the treatment of refractory melasma: a randomized controlled trial.
Topics: Erbium; Female; Humans; Hydroquinones; Lasers, Solid-State; Melanosis; Tranexamic Acid; Treatment Ou | 2022 |
Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma: A randomized, self-controlled, split-face study.
Topics: Administration, Cutaneous; Adult; Antifibrinolytic Agents; China; Elasticity; Erythema; Face; Female | 2017 |
Therapeutic efficacy and safety of oral tranexamic acid and that of tranexamic acid local infiltration with microinjections in patients with melasma: a comparative study.
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Injections, Intradermal; Male; Melanosis; M | 2017 |
Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma.
Topics: Administration, Oral; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Therapy, Combination | 2018 |
Comparing the efficacy of topical hydroquinone 2% versus intradermal tranexamic acid microinjections in treating melasma: a split-face controlled trial.
Topics: Administration, Topical; Adult; Erythema; Face; Female; Humans; Hydroquinones; Melanins; Melanosis; | 2018 |
Topical 3% tranexamic acid enhances the efficacy of 1064-nm Q-switched neodymium-doped yttrium aluminum garnet laser in the treatment of melasma.
Topics: Administration, Cutaneous; Adult; Antifibrinolytic Agents; Chemotherapy, Adjuvant; Combined Modality | 2018 |
Assessment of combined fractional CO
Topics: Administration, Cutaneous; Administration, Topical; Adult; Carbon Dioxide; Combined Modality Therapy | 2019 |
Clinical observation on tranexamic acid combined with reduced glutathione for the treatment of chloasma.
Topics: Administration, Cutaneous; Adult; Drug Therapy, Combination; Female; Glutathione; Humans; Hydroquino | 2018 |
Analysis of the effect of different doses of oral tranexamic acid on melasma: a multicentre prospective study.
Topics: Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Hu | 2019 |
Treatment of melasma with oral administration of compound tranexamic acid: a preliminary clinical trial.
Topics: Administration, Oral; Adult; Female; Humans; Male; Melanosis; Middle Aged; Prospective Studies; Tran | 2014 |
Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma.
Topics: Adult; Dermatologic Agents; Double-Blind Method; Female; Humans; Hydroquinones; Liposomes; Melanosis | 2015 |
Topical tranexamic acid as an adjuvant treatment in melasma: Side-by-side comparison clinical study.
Topics: Administration, Topical; Adult; Asian People; Combined Modality Therapy; Face; Female; Humans; Low-L | 2016 |
Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a shor
Topics: Administration, Oral; Administration, Topical; Adult; Drug Therapy, Combination; Female; Follow-Up S | 2017 |
Effect of tranexamic acid on melasma: a clinical trial with histological evaluation.
Topics: Administration, Topical; Adult; Aged; Female; Humans; Melanosis; Middle Aged; Tranexamic Acid; Young | 2013 |
Effect of tranexamic acid on melasma: a clinical trial with histological evaluation.
Topics: Administration, Topical; Adult; Aged; Female; Humans; Melanosis; Middle Aged; Tranexamic Acid; Young | 2013 |
Effect of tranexamic acid on melasma: a clinical trial with histological evaluation.
Topics: Administration, Topical; Adult; Aged; Female; Humans; Melanosis; Middle Aged; Tranexamic Acid; Young | 2013 |
Effect of tranexamic acid on melasma: a clinical trial with histological evaluation.
Topics: Administration, Topical; Adult; Aged; Female; Humans; Melanosis; Middle Aged; Tranexamic Acid; Young | 2013 |
Topical 5% tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial.
Topics: Administration, Cutaneous; Adult; Antifibrinolytic Agents; Asian People; Bleaching Agents; Double-Bl | 2012 |
51 other studies available for tranexamic acid and Chloasma
| Article | Year |
|---|---|
Clinico-epidemiological profile and long term follow up in melasma.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; India; Melanosis; Tranexamic Acid; Tre | 2021 |
Split-face comparative study between intradermal tranexamic acid injection alone versus intradermal tranexamic acid injection combined with Q-switched Nd:YAG laser in melasma treatment: dermoscopic and clinical evaluation.
Topics: Female; Humans; Lasers, Solid-State; Low-Level Light Therapy; Melanosis; Tranexamic Acid; Treatment | 2022 |
Tranexamic Acid Microinjection Alone Versus Its Combination With Fractional Carbon Dioxide Laser in Melasma Treatment: A Dermoscopic Evaluation.
Topics: Humans; Lasers, Gas; Melanins; Melanosis; Microinjections; Pigmentation Disorders; Tranexamic Acid; | 2022 |
Comparison of fractional erbium:YAG laser-assisted tranexamic acid delivery alone and in combination with oral tranexamic acid in melasma.
Topics: Erbium; Humans; Lasers, Solid-State; Melanosis; Retrospective Studies; Tranexamic Acid; Treatment Ou | 2022 |
Oral Tranexamic Acid for the Treatment of Melasma: A Case Series and Novel Dosing Regimen.
Topics: Administration, Cutaneous; Humans; Melanosis; Quality of Life; Tranexamic Acid; Treatment Outcome | 2022 |
Comparison of clinical results of oral tranexamic acid and platelet rich plasma therapies in melasma treatment.
Topics: Administration, Oral; Adult; Humans; Melanosis; Middle Aged; Platelet-Rich Plasma; Retrospective Stu | 2022 |
A comparative evaluation of the efficacy of intralesional tranexamic acid versus platelet rich plasma in the treatment of melasma.
Topics: Adult; Female; Humans; Male; Melanosis; Microinjections; Middle Aged; Platelet-Rich Plasma; Tranexam | 2022 |
1927nm Fractional Diode Laser and Oral Tranexamic Acid for Melasma: A 5.7-Year Summary on Safety and Effectiveness.
Topics: Antifibrinolytic Agents; Humans; Lasers, Semiconductor; Melanosis; Tranexamic Acid; Treatment Outcom | 2022 |
Evaluation of oral tranexamic acid as a novel treatment for melasma with a high benefit-risk ratio.
Topics: Female; Humans; Hyperpigmentation; Melanosis; Menorrhagia; Odds Ratio; Quality of Life; Retrospectiv | 2022 |
Design and development of tranexamic acid loaded film-forming gel to alleviate melasma.
Topics: Animals; Epidermis; Hyperpigmentation; Melanocytes; Melanosis; Mice; Polymers; Tranexamic Acid | 2022 |
Tranexamic acid may promote melanocores clustering in keratinocytes through upregulation of Rab5b.
Topics: Humans; Keratinocytes; Melanins; Melanosis; Tranexamic Acid; Up-Regulation | 2023 |
Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study.
Topics: Humans; Injections, Intradermal; Melanosis; Platelet-Rich Plasma; Prospective Studies; Tranexamic Ac | 2023 |
Intradermal application of tranexamic acid (TA) as treatment of melasma in the out-patients department of a public sector hospital: A pilot study.
Topics: Hospitals, Public; Humans; Melanosis; Outpatients; Pilot Projects; Public Sector; Tranexamic Acid; T | 2022 |
Efficacy and safety of the combination of tranexamic acid injection and electro-optical synergy (ELOS) versus tranexamic acid injection alone in the treatment of melasma.
Topics: Humans; Melanosis; Patient Satisfaction; Retrospective Studies; Tranexamic Acid; Treatment Outcome | 2023 |
Efficacy of photorejuvenation combined with tranexamic acid and hydroquinone cream in the treatment of complex facial pigmentation.
Topics: Humans; Hydroquinones; Melanosis; Pigmentation; Retrospective Studies; Tranexamic Acid; Water | 2023 |
Assessment of the Efficacy of Tranexamic Acid Solution 5% in the Treatment of Melasma in Patients of South Asian Descent.
Topics: Administration, Oral; Administration, Topical; Humans; Melanosis; South Asian People; Tranexamic Aci | 2023 |
Melasma: A critical analysis of clinical trials investigating treatment modalities published in the past 10 years.
Topics: Administration, Cutaneous; Administration, Oral; Chemexfoliation; Clinical Trials as Topic; Combined | 2020 |
A comparative study between oral tranexamic acid versus oral tranexamic acid and Q-switched Nd-YAG laser in melasma treatment: a clinical and dermoscopic evaluation.
Topics: Humans; Lasers, Solid-State; Melanosis; Severity of Illness Index; Tranexamic Acid; Treatment Outcom | 2021 |
In vitro human skin concentrations following topical application of 2% tranexamic acid in co-enhancer cream and branded cream formulations.
Topics: Administration, Cutaneous; Humans; Melanosis; Ointments; Skin; Skin Cream; Tranexamic Acid | 2020 |
A cross-sectional report on melasma among Hispanic patients: Evaluating the role of oral tranexamic acid versus oral tranexamic acid plus hydroquinone.
Topics: Administration, Oral; Adolescent; Adult; Cross-Sectional Studies; Drug Combinations; Female; Hispani | 2020 |
Refining the management of hyperpigmentary disorders.
Topics: Dermatologists; Humans; Hyperpigmentation; Melanosis; Patient Care Management; Quality of Life; Self | 2020 |
Hypopigmentation as a side effect of melasma treatment with tranexamic acid intradermal microinjections.
Topics: Antifibrinolytic Agents; Humans; Hypopigmentation; Melanosis; Microinjections; Tranexamic Acid | 2020 |
A split face comparative study between intradermal tranexamic acid and Erbium-YAG laser in treatment of melasma.
Topics: Erbium; Humans; Lasers, Solid-State; Melanosis; Tranexamic Acid; Treatment Outcome | 2022 |
Micro-needling versus fractional carbon dioxide laser for delivery of tranexamic acid in the treatment of melasma: A split-face study.
Topics: Combined Modality Therapy; Female; Humans; Lasers, Gas; Low-Level Light Therapy; Melanosis; Tranexam | 2021 |
Efficacy and safety of tranexamic acid 5% cream vs hydroquinone 4% cream in treating melasma: A split-face comparative clinical, histopathological, and antera 3D camera study.
Topics: Female; Humans; Hydroquinones; Melanosis; Quality of Life; Tranexamic Acid; Treatment Outcome | 2020 |
Dynamic Optical Coherence Tomography of Cutaneous Blood Vessels in Melasma and Vessel Response to Oral Tranexamic Acid.
Topics: Humans; Lasers; Melanosis; Tomography, Optical Coherence; Tranexamic Acid | 2021 |
Laser-assisted delivery of tranexamic acid for melasma: Pilot study using a novel 1927 nm fractional thulium fiber laser.
Topics: Humans; Lasers; Melanosis; Pilot Projects; Prospective Studies; Quality of Life; Thulium; Tranexamic | 2021 |
Dermoscopic evaluation of tranexamic acid versus Vitamin C, with microneedling in the treatment of melasma: a comparative, split-face, single-blinded study.
Topics: Ascorbic Acid; Dermatologic Surgical Procedures; Female; Humans; Melanosis; Needles; Single-Blind Me | 2022 |
The Use of Tranexamic Acid to Prevent and Treat Post-Inflammatory Hyperpigmentation.
Topics: Acne Vulgaris; Administration, Oral; Adult; Anesthetics, Local; Chemexfoliation; Drug Combinations; | 2021 |
Novel dissolving microneedles preparation for synergistic melasma therapy: Combined effects of tranexamic acid and licorice extract.
Topics: Administration, Cutaneous; Animals; Glycyrrhiza; Guinea Pigs; Melanosis; Plant Extracts; Tranexamic | 2021 |
Liposomal azelaic acid 20% cream vs hydroquinone 4% cream as adjuvant to oral tranexamic acid in melasma: a comparative study.
Topics: Adjuvants, Immunologic; Dermatologic Agents; Dicarboxylic Acids; Emollients; Female; Humans; Hydroqu | 2022 |
Feasibility of oral tranexamic acid for vitiligo patients with melasma.
Topics: Feasibility Studies; Humans; Melanosis; Retrospective Studies; Tranexamic Acid; Treatment Outcome; V | 2021 |
Topical 5% tranexamic acid with 30% glycolic acid peel: An useful combination for accelerating the improvement in melasma.
Topics: Chemexfoliation; Glycolates; Humans; Melanosis; Quality of Life; Tranexamic Acid; Treatment Outcome | 2021 |
Tranexamic acid inhibits melanogenesis by activating the autophagy system in cultured melanoma cells.
Topics: Animals; Autophagosomes; Autophagy; Autophagy-Related Protein 5; Cell Line, Tumor; Down-Regulation; | 2017 |
Systemic treatments for melasma: adjuvant therapy with a novel topical agent.
Topics: Administration, Oral; Administration, Topical; Adult; Cohort Studies; Drug Therapy, Combination; Fem | 2018 |
Melasma treatment with oral tranexamic acid and a novel adjuvant topical therapy.
Topics: Angiogenesis Inhibitors; Antifibrinolytic Agents; Aromatase Inhibitors; Drug Therapy, Combination; E | 2018 |
Efficacy of oral tranexemic acid in refractory melasma: A clinico-immuno-histopathological study.
Topics: Administration, Oral; Adult; Antifibrinolytic Agents; Female; Humans; Immunohistochemistry; Male; MA | 2018 |
A pilot study of oral tranexamic acid and Glycyrrhizin compound in the treatment of recalcitrant Riehl's melanosis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Antifibrinolytic Agents; Dermoscopy; Drug The | 2019 |
Oral tranexamic acid for the treatment of melasma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antifibrinolytic Agents; Female; Humans; Male; Melano | 2019 |
Combination of Oral Tranexamic Acid with Topical 3% Tranexamic Acid versus Oral Tranexamic Acid with Topical 20% Azelaic Acid in the Treatment of Melasma.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Antifibrinolytic Agents; Combined Modality T | 2019 |
JAAD Game Changers: Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma.
Topics: Antifibrinolytic Agents; Double-Blind Method; Humans; Melanosis; Tranexamic Acid | 2019 |
Efficacy of topical tranexmic acid in the treatment of melasma.
Topics: Administration, Topical; Humans; Melanosis; Tranexamic Acid; Treatment Outcome | 2016 |
Efficacy and possible mechanisms of topical tranexamic acid in melasma.
Topics: Adult; Antifibrinolytic Agents; Biomarkers; Endothelin-1; Female; Humans; Immunohistochemistry; Mela | 2016 |
Efficacy and possible mechanisms of topical tranexamic acid in melasma.
Topics: Adult; Antifibrinolytic Agents; Biomarkers; Endothelin-1; Female; Humans; Immunohistochemistry; Mela | 2016 |
Efficacy and possible mechanisms of topical tranexamic acid in melasma.
Topics: Adult; Antifibrinolytic Agents; Biomarkers; Endothelin-1; Female; Humans; Immunohistochemistry; Mela | 2016 |
Efficacy and possible mechanisms of topical tranexamic acid in melasma.
Topics: Adult; Antifibrinolytic Agents; Biomarkers; Endothelin-1; Female; Humans; Immunohistochemistry; Mela | 2016 |
Oral tranexamic acid lightens refractory melasma.
Topics: Administration, Oral; Adult; Antifibrinolytic Agents; Female; Humans; Male; Melanosis; Middle Aged; | 2017 |
Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis.
Topics: Administration, Oral; Adult; Asian People; Dermatologic Agents; Facial Dermatoses; Female; Gastroint | 2016 |
Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis.
Topics: Administration, Oral; Adult; Asian People; Dermatologic Agents; Facial Dermatoses; Female; Gastroint | 2016 |
Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis.
Topics: Administration, Oral; Adult; Asian People; Dermatologic Agents; Facial Dermatoses; Female; Gastroint | 2016 |
Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis.
Topics: Administration, Oral; Adult; Asian People; Dermatologic Agents; Facial Dermatoses; Female; Gastroint | 2016 |
A pilot study for triple combination therapy with a low-fluence 1064 nm Q-switched Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's Melanosis.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Combined Modality Therapy; Erythema; Facial | 2017 |
The effects of hydroporation on melasma with anti-aging cocktail.
Topics: Antifibrinolytic Agents; beta-Glucans; Collagen Type IV; Copper; Dermatologic Agents; Dermis; Drug C | 2017 |
Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd:YAG laser.
Topics: Administration, Oral; Adult; Antifibrinolytic Agents; Combined Modality Therapy; Female; Humans; Las | 2013 |
Treatment of melasma with oral administration of tranexamic acid.
Topics: Administration, Oral; Adult; Asian People; China; Dermatologic Agents; Female; Humans; Male; Melanos | 2012 |
Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial.
Topics: Adult; Antifibrinolytic Agents; Female; Humans; Injections, Intradermal; Melanosis; Microinjections; | 2006 |
New approach to the evaluation of skin color of pigmentary lesions using Skin Tone Color Scale.
Topics: Adolescent; Adult; Aged; Ascorbic Acid; Dermatologic Agents; Dermatology; Face; Female; Humans; Hype | 2007 |